In the news:
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy - Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca - China has trapped the tiger of AstraZeneca's growth - AstraZeneca embarks on major US expansion - AstraZeneca Talks Up US Growth as China Problems Worsen - China fright ups the stakes for AstraZeneca - AstraZeneca's top China executive detained by authorities - Report finds China targeted AstraZeneca in fraud probe over cancer treatment - China Has Detained a Senior AstraZeneca Executive - AstraZeneca Says Current, Former Executives Involved in China Probe
AstraZeneca
Save
ShareKey facts
- city: Cambridge
- country: United Kingdom
- sector: Health Care
- foundation year: 1999
- industry: Pharmaceuticals
- CEO: Pascal Soriot D.V.M., M.B.A.
Classified as: organization
Summary
AstraZeneca is a company. It is located in Cambridge, the United Kingdom and was founded in 1999. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Business
AstraZeneca is one of the companies in the United Kingdom, companies in Pharmaceuticals, companies in Health Care and 3,466,499 companies in our database.
- Assets: 105.4B $
- Debt: 31.4B $
- Employees: 83,100 people
- Free cash flow: 3.8B $
- Market cap: 184.7B $
- Profits: 112M $
- Revenues: 44B $
Stocks from AstraZeneca
Explore more on business
Talking Points:
- AstraZenecaResearchBased BioPharmaceutical Company
- AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
- We're transforming the future of healthcare by unlocking the power of what science can do. Community Guidelines: https://t.co/Kh08zUdFpT
- What science can do | AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation ...
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Learn more about talking points